AstraZeneca Q2 EPS beats expectations as revenue growth holds steady

The UK pharma giant reported an 18% rise in core earnings per share to $2.63, surpassing consensus estimates while maintaining its full-year outlook.

By Handelsavisen Newsroom · Automated 2026-07-27 06:26 UTC · 1 min read

AstraZeneca delivered a second-quarter earnings beat, reporting core earnings per share of $2.63 for the three months ended June 30.

The figure represents an 18% increase year-over-year and exceeded the consensus estimate of $2.48 per share compiled by analysts.

39 billion. The results underscore the company’s ability to drive profitability growth even as top-line expansion remains moderate.

Total revenue also climbed 5% to $15.38 billion at constant-currency rates, closely tracking the expected $15.39 billion.

The results underscore the company’s ability to drive profitability growth even as top-line expansion remains moderate.

By beating profit expectations while holding its full-year outlook, AstraZeneca signals confidence in its pipeline execution and commercial strategy.

The performance aligns with a broader trend among major pharmaceutical peers, including recent strong quarterly reports from Johnson & Johnson and Novartis, which also exceeded market expectations on the back of robust demand in oncology and immunology portfolios.